HERON THERAPEUTICS, INC. /DE/ Selling and Marketing Expense
HERON THERAPEUTICS, INC. /DE/ (HRTX) reported Selling and Marketing Expense of $14.16 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2026-08-10
- HERON THERAPEUTICS, INC. /DE/ selling and marketing expense for the quarter ending 2026-06-30 was $14.16M, a 22.33% increase year-over-year.
- HERON THERAPEUTICS, INC. /DE/ selling and marketing expense for the quarter ending 2026-03-31 was $14.31M, a 16.22% increase year-over-year.
- HERON THERAPEUTICS, INC. /DE/ selling and marketing expense for the quarter ending 2025-12-31 was $12.23M, a 10.64% increase year-over-year.
- HERON THERAPEUTICS, INC. /DE/ selling and marketing expense for the quarter ending 2025-09-30 was $12.94M, a 17.95% increase year-over-year.
- HERON THERAPEUTICS, INC. /DE/ selling and marketing expense for fiscal 2025 was $49.06M, a 4.20% increase from fiscal 2024.
- HERON THERAPEUTICS, INC. /DE/ selling and marketing expense for fiscal 2024 was $47.09M, a 30.39% decline from fiscal 2023.
- HERON THERAPEUTICS, INC. /DE/ selling and marketing expense for fiscal 2023 was $67.64M, a 18.02% decline from fiscal 2022.
- HERON THERAPEUTICS, INC. /DE/ selling and marketing expense for fiscal 2022 was $82.51M, a 5.35% decline from fiscal 2021.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 6 month | Selling and Marketing Expense 9 month | Selling and Marketing Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.16M 10-Q · filed 2026-08-10 | $28.47M 10-Q · filed 2026-08-10 | $40.70M derived: sum of 3 quarters · filed 2026-08-10 | $53.64M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $14.31M 10-Q · filed 2026-05-11 | $26.54M derived: sum of 2 quarters · filed 2026-05-11 | $39.48M derived: sum of 3 quarters · filed 2026-05-11 | $51.06M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $12.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $25.18M derived: sum of 2 quarters · filed 2026-02-26 | $36.75M derived: sum of 3 quarters · filed 2026-08-10 | $49.06M 10-K · filed 2026-02-26 |
| 2025-09-30 | $12.94M 10-Q · filed 2025-11-04 | $24.52M derived: sum of 2 quarters · filed 2026-08-10 | $36.83M 10-Q · filed 2025-11-04 | $47.88M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $11.57M 10-Q · filed 2026-08-10 | $23.89M 10-Q · filed 2026-08-10 | $34.94M derived: sum of 3 quarters · filed 2026-08-10 | $45.91M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $12.31M 10-Q · filed 2026-05-11 | $23.37M derived: sum of 2 quarters · filed 2026-05-11 | $34.34M derived: sum of 3 quarters · filed 2026-05-11 | $47.95M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $11.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $22.03M derived: sum of 2 quarters · filed 2026-02-26 | $35.64M derived: sum of 3 quarters · filed 2026-02-26 | $47.09M 10-K · filed 2026-02-26 |
| 2024-09-30 | $10.97M 10-Q · filed 2025-11-04 | $24.59M derived: sum of 2 quarters · filed 2025-11-04 | $36.03M 10-Q · filed 2025-11-04 | $48.36M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $13.61M 10-Q · filed 2025-08-08 | $25.06M 10-Q · filed 2025-08-08 | $37.38M derived: sum of 3 quarters · filed 2026-02-26 | $50.34M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $11.44M 10-Q · filed 2025-05-06 | $23.77M derived: sum of 2 quarters · filed 2026-02-26 | $36.73M derived: sum of 3 quarters · filed 2026-02-26 | $57.93M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $12.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $25.28M derived: sum of 2 quarters · filed 2026-02-26 | $46.49M derived: sum of 3 quarters · filed 2026-02-26 | $67.64M 10-K · filed 2026-02-26 |
| 2023-09-30 | $12.96M 10-Q · filed 2024-11-12 | $34.16M derived: sum of 2 quarters · filed 2024-11-12 | $55.31M 10-Q · filed 2024-11-12 | $73.09M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $21.20M 10-Q · filed 2024-08-06 | $42.36M 10-Q · filed 2024-08-06 | $60.13M derived: sum of 3 quarters · filed 2025-02-27 | $78.51M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $21.15M 10-Q · filed 2024-05-07 | $38.93M derived: sum of 2 quarters · filed 2025-02-27 | $57.31M derived: sum of 3 quarters · filed 2025-02-27 | $80.25M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $17.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $36.15M derived: sum of 2 quarters · filed 2025-02-27 | $59.09M derived: sum of 3 quarters · filed 2025-02-27 | $82.51M 10-K · filed 2025-02-27 |
| 2022-09-30 | $18.38M 10-Q · filed 2023-11-14 | $41.32M derived: sum of 2 quarters · filed 2023-11-14 | $64.74M 10-Q · filed 2023-11-14 | $89.22M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $22.94M 10-Q · filed 2023-08-14 | $46.36M 10-Q · filed 2023-08-14 | $70.85M derived: sum of 3 quarters · filed 2023-08-14 | $96.05M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $23.42M 10-Q · filed 2023-05-11 | $47.91M derived: sum of 2 quarters · filed 2023-05-11 | $73.11M derived: sum of 3 quarters · filed 2023-05-11 | $95.36M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $24.49M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $49.69M derived: sum of 2 quarters · filed 2023-03-29 | $71.94M derived: sum of 3 quarters · filed 2023-03-29 | $87.18M 10-K · filed 2023-03-29 |
| 2021-09-30 | $25.21M 10-Q · filed 2022-11-08 | $47.46M derived: sum of 2 quarters · filed 2022-11-08 | $62.69M 10-Q · filed 2022-11-08 | $78.25M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $22.25M 10-Q · filed 2022-08-09 | $37.49M 10-Q · filed 2022-08-09 | $53.04M derived: sum of 3 quarters · filed 2022-08-09 | $65.55M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $15.24M 10-Q · filed 2022-05-09 | $30.79M derived: sum of 2 quarters · filed 2022-05-09 | $43.30M derived: sum of 3 quarters · filed 2022-05-09 | $58.89M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $15.55M 10-K · filed 2021-02-24 | $28.07M derived: sum of 2 quarters · filed 2021-11-03 | $43.66M derived: sum of 3 quarters · filed 2021-11-03 | $63.85M 10-K · filed 2022-02-28 |
| 2020-09-30 | $12.52M 10-Q · filed 2021-11-03 | $28.10M derived: sum of 2 quarters · filed 2021-11-03 | $48.30M 10-Q · filed 2021-11-03 | $68.72M derived: sum of 4 quarters · filed 2021-11-03 |
| 2020-06-30 | $15.59M 10-Q · filed 2021-08-09 | $35.78M 10-Q · filed 2021-08-09 | $56.20M derived: sum of 3 quarters · filed 2021-08-09 | $73.18M derived: sum of 4 quarters · filed 2021-08-09 |
| 2020-03-31 | $20.20M 10-Q · filed 2021-05-10 | $40.62M derived: sum of 2 quarters · filed 2021-05-10 | $57.59M derived: sum of 3 quarters · filed 2021-05-10 | $81.24M derived: sum of 4 quarters · filed 2021-05-10 |
| 2019-12-31 | $20.42M 10-K · filed 2021-02-24 | $37.40M derived: sum of 2 quarters · filed 2021-02-24 | $61.04M derived: sum of 3 quarters · filed 2021-02-24 | $89.76M 10-K · filed 2022-02-28 |
| 2019-09-30 | $16.98M 10-K · filed 2021-02-24 | $40.62M derived: sum of 2 quarters · filed 2021-02-24 | $69.34M 10-Q · filed 2020-11-05 | $89.30M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $23.65M 10-K · filed 2021-02-24 | $52.37M 10-Q · filed 2020-08-05 | $72.32M derived: sum of 3 quarters · filed 2021-02-24 | $88.61M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $28.72M 10-K · filed 2021-02-24 | $48.68M derived: sum of 2 quarters · filed 2021-02-24 | $64.96M derived: sum of 3 quarters · filed 2021-02-24 | $79.49M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | $19.96M 10-K · filed 2020-03-02 | $36.24M derived: sum of 2 quarters · filed 2020-03-02 | $50.77M derived: sum of 3 quarters · filed 2020-03-02 | $64.60M 10-K · filed 2021-02-24 |
| 2018-09-30 | $16.28M 10-K · filed 2020-03-02 | $30.81M derived: sum of 2 quarters · filed 2020-03-02 | $44.65M 10-Q · filed 2019-11-12 | $61.33M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $14.53M 10-K · filed 2020-03-02 | $28.37M 10-Q · filed 2019-08-05 | $45.05M derived: sum of 3 quarters · filed 2020-03-02 | $58.58M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $13.84M 10-K · filed 2020-03-02 | $30.52M derived: sum of 2 quarters · filed 2020-03-02 | $44.05M derived: sum of 3 quarters · filed 2020-03-02 | $58.82M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $16.68M 10-K · filed 2019-02-22 | $30.21M derived: sum of 2 quarters · filed 2019-02-22 | $44.98M derived: sum of 3 quarters · filed 2019-02-22 | $56.60M 10-K · filed 2020-03-02 |
| 2017-09-30 | $13.53M 10-K · filed 2019-02-22 | $28.30M derived: sum of 2 quarters · filed 2019-02-22 | $39.92M 10-Q · filed 2018-11-07 | $52.57M derived: sum of 4 quarters · filed 2019-02-22 |
| 2017-06-30 | $14.77M 10-K · filed 2019-02-22 | $26.39M 10-Q · filed 2018-08-08 | $39.04M derived: sum of 3 quarters · filed 2019-02-22 | $51.20M derived: sum of 4 quarters · filed 2019-02-22 |
| 2017-03-31 | $11.62M 10-K · filed 2019-02-22 | $24.27M derived: sum of 2 quarters · filed 2019-02-22 | $36.43M derived: sum of 3 quarters · filed 2019-02-22 | $47.43M derived: sum of 4 quarters · filed 2019-02-22 |
| 2016-12-31 | $12.65M 10-K · filed 2018-02-27 | $24.81M derived: sum of 2 quarters · filed 2018-02-27 | $35.81M derived: sum of 3 quarters · filed 2018-02-27 | $47.67M 10-K · filed 2019-02-22 |
| 2016-09-30 | $12.16M 10-K · filed 2018-02-27 | $23.16M derived: sum of 2 quarters · filed 2018-02-27 | $35.02M 10-Q · filed 2017-11-06 | $43.22M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-06-30 | $11.01M 10-K · filed 2018-02-27 | $22.86M 10-Q · filed 2017-08-09 | $31.06M derived: sum of 3 quarters · filed 2018-02-27 | $35.18M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-03-31 | $11.85M 10-K · filed 2018-02-27 | $20.05M derived: sum of 2 quarters · filed 2018-02-27 | $24.17M derived: sum of 3 quarters · filed 2018-02-27 | $26.93M derived: sum of 4 quarters · filed 2018-02-27 |
| 2015-12-31 | $8.20M 10-K · filed 2017-02-23 | $12.32M derived: sum of 2 quarters · filed 2017-02-23 | $15.08M derived: sum of 3 quarters · filed 2017-02-23 | $17.35M 10-K · filed 2018-02-27 |
| 2015-09-30 | $4.12M 10-K · filed 2017-02-23 | $6.88M derived: sum of 2 quarters · filed 2017-02-23 | $9.15M 10-Q · filed 2016-11-08 | |
| 2015-06-30 | $2.76M 10-K · filed 2017-02-23 | $5.03M 10-Q · filed 2016-08-08 | ||
| 2015-03-31 | $2.27M 10-K · filed 2017-02-23 | |||
| 2014-12-31 | $8.71M 10-K · filed 2017-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Lite Strategy, Inc. (LITS) | United States | $0.049B |